These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8836272)

  • 1. Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis.
    Costela JL; Jiménez R; Calvo R; Suárez E; Carlos R
    Acta Anaesthesiol Scand; 1996 Jul; 40(6):741-5. PubMed ID: 8836272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction.
    de la Fuente L; Lukas JC; Vázquez JA; Jauregizar N; Calvo R; Suárez E
    Eur J Clin Pharmacol; 2002 Dec; 58(9):615-9. PubMed ID: 12483454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma protein binding of etomidate in patients with renal failure or hepatic cirrhosis.
    Carlos R; Calvo R; Erill S
    Clin Pharmacokinet; 1979; 4(2):144-8. PubMed ID: 455872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of lipoproteins in serum binding variations of propofol.
    Zamacona MK; Suárez E; García E; Aguirre C; Calvo R
    Anesth Analg; 1998 Nov; 87(5):1147-51. PubMed ID: 9806699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass.
    Takizawa E; Hiraoka H; Takizawa D; Goto F
    Br J Anaesth; 2006 Feb; 96(2):179-85. PubMed ID: 16339790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Ganansia J; Bianchetti G; Morselli PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs.
    Pacifici GM; Viani A; Taddeucci-Brunelli G; Rizzo G; Carrai M; Schulz HU
    Ther Drug Monit; 1986; 8(3):259-63. PubMed ID: 3750366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of propofol to human serum albumin.
    Schywalsky M; Ihmsen H; Knoll R; Schwilden H
    Arzneimittelforschung; 2005; 55(6):303-6. PubMed ID: 16032968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum protein binding of propofol in critically ill patients.
    Zamacona MK; Suárez E; Aguilera L; Rodríguez-Sasiaín ; Aguirre C; Calvo R
    Acta Anaesthesiol Scand; 1997 Nov; 41(10):1267-72. PubMed ID: 9422291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of intermittent hemodialysis (HD) on bispectral index (scale) (BIS) and serum propofol concentration under postoperative intravenous sedation].
    Tatebayashi S; Imai Y; Ohgi K; Tamaki S; Yamamoto K; Takahashi M; Kurehara K; Furuya H; Kirita T
    Masui; 2004 May; 53(5):508-13. PubMed ID: 15198233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding.
    Hiraoka H; Yamamoto K; Okano N; Morita T; Goto F; Horiuchi R
    Clin Pharmacol Ther; 2004 Apr; 75(4):324-30. PubMed ID: 15060510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency.
    Grafnetterová J; Vodrázka Z; Jandová D; Schück O; Tomásek R; Lachmanová J
    Clin Nephrol; 1976 Oct; 6(4):448-50. PubMed ID: 975643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of serum protein binding of felodipine.
    Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
    Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein binding of thiopental in patients with impaired renal or hepatic function.
    Ghoneim MM; Pandya H
    Anesthesiology; 1975 May; 42(5):545-9. PubMed ID: 1130720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propofol binding to human blood proteins.
    Altmayer P; Büch U; Büch HP
    Arzneimittelforschung; 1995 Oct; 45(10):1053-6. PubMed ID: 8595056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of propofol concentration in human plasma on free fraction of the drug.
    Dawidowicz AL; Kalitynski R; Kobielski M; Pieniadz J
    Chem Biol Interact; 2006 Feb; 159(2):149-55. PubMed ID: 16318847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of target-controlled infusion for propofol in patients with chronic renal failure undergoing living-related renal transplantation].
    Igarashi T; Nagata O; Iwakiri H; Ikeda M; Ozaki M
    Masui; 2009 Sep; 58(9):1143-8. PubMed ID: 19764438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.
    Zini R; Morin D; Salvadori C; Tillement JP
    Br J Clin Pharmacol; 1990 Jan; 29(1):9-18. PubMed ID: 2297464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of unbound propofol concentrations in a diabetic population.
    de la Fuente L; Lukas JC; Jauregizar N; Vázquez JA; Calvo R; Suárez E
    Ther Drug Monit; 2002 Dec; 24(6):689-95. PubMed ID: 12451283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.